Stay updated on BIONIKK Trial: Nivolumab vs VEGFR tKi in Kidney Cancer
Sign up to get notified when there's something new on the BIONIKK Trial: Nivolumab vs VEGFR tKi in Kidney Cancer page.

Latest updates to the BIONIKK Trial: Nivolumab vs VEGFR tKi in Kidney Cancer page
- CheckyesterdayChange DetectedThe webpage has been updated to include new drug information for Nivolumab and Pazopanib, as well as additional details about clear-cell metastatic renal cell carcinoma. However, several previous entries related to drug classifications and genetic resources have been removed.SummaryDifference5%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check22 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.0%
- Check30 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.5%
- Check37 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.SummaryDifference0.1%
- Check44 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.0%
Stay in the know with updates to BIONIKK Trial: Nivolumab vs VEGFR tKi in Kidney Cancer
Enter your email address, and we'll notify you when there's something new on the BIONIKK Trial: Nivolumab vs VEGFR tKi in Kidney Cancer page.